Hiroko Hirooka

532 total citations
11 papers, 369 citations indexed

About

Hiroko Hirooka is a scholar working on Cell Biology, Molecular Biology and Clinical Biochemistry. According to data from OpenAlex, Hiroko Hirooka has authored 11 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cell Biology, 4 papers in Molecular Biology and 4 papers in Clinical Biochemistry. Recurrent topics in Hiroko Hirooka's work include Aldose Reductase and Taurine (6 papers), Advanced Glycation End Products research (4 papers) and Neuroscience and Neuropharmacology Research (2 papers). Hiroko Hirooka is often cited by papers focused on Aldose Reductase and Taurine (6 papers), Advanced Glycation End Products research (4 papers) and Neuroscience and Neuropharmacology Research (2 papers). Hiroko Hirooka collaborates with scholars based in Japan, United States and United Kingdom. Hiroko Hirooka's co-authors include Irina G. Obrosova, Csaba Szabó, Martin J. Stevens, Pál Pacher, Mark A. Yorek, Zsuzsanna K. Zsengellér, Ikuo Hayasaka, Atsushi Miyachi, Takayuki Negishi and Yasuhiro Yoshikawa and has published in prestigious journals such as Diabetes, Biochemical and Biophysical Research Communications and Annals of the New York Academy of Sciences.

In The Last Decade

Hiroko Hirooka

11 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroko Hirooka Japan 8 107 97 90 77 59 11 369
Teresa Chen United States 6 56 0.5× 26 0.3× 175 1.9× 27 0.4× 14 0.2× 10 381
Mahmood Mozaffari United States 5 148 1.4× 187 1.9× 107 1.2× 41 0.5× 12 0.2× 7 415
Kiyoshi Omura Japan 12 166 1.6× 69 0.7× 165 1.8× 68 0.9× 42 0.7× 38 482
Pere Julià Spain 10 66 0.6× 121 1.2× 247 2.7× 28 0.4× 5 0.1× 15 532
С. И. Ковтун United States 13 85 0.8× 23 0.2× 222 2.5× 118 1.5× 15 0.3× 34 431
G Auricchio Italy 11 109 1.0× 38 0.4× 204 2.3× 101 1.3× 11 0.2× 44 414
Y. Suresh India 9 122 1.1× 10 0.1× 163 1.8× 63 0.8× 19 0.3× 15 555
M Hayakawa Japan 14 99 0.9× 14 0.1× 311 3.5× 97 1.3× 10 0.2× 27 518
Aniruddh Kapoor United States 6 53 0.5× 72 0.7× 90 1.0× 29 0.4× 4 0.1× 9 276

Countries citing papers authored by Hiroko Hirooka

Since Specialization
Citations

This map shows the geographic impact of Hiroko Hirooka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Hirooka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Hirooka more than expected).

Fields of papers citing papers by Hiroko Hirooka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroko Hirooka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Hirooka. The network helps show where Hiroko Hirooka may publish in the future.

Co-authorship network of co-authors of Hiroko Hirooka

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroko Hirooka. A scholar is included among the top collaborators of Hiroko Hirooka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroko Hirooka. Hiroko Hirooka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Hirooka, Hiroko, et al.. (2013). Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs. European Journal of Drug Metabolism and Pharmacokinetics. 38(2). 87–96. 8 indexed citations
2.
Stavniichuk, Roman, Hanna Shevalye, Hiroko Hirooka, Jerry L. Nadler, & Irina G. Obrosova. (2012). Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy. Biochemical Pharmacology. 83(7). 932–940. 29 indexed citations
3.
Sango, Kazunori, Hiroko Yanagisawa, Koichi Kato, et al.. (2008). Differential Effects of High Glucose and Methylglyoxal on Viability and Polyol Metabolism in Immortalized Adult Mouse Schwann Cells. 1(1). 1–11. 7 indexed citations
4.
Negishi, Takayuki, et al.. (2006). Toxicokinetics of bisphenol A in rats, monkeys and chimpanzees by the LC–MS/MS method. Toxicology. 226(2-3). 208–217. 68 indexed citations
5.
Sango, Kazunori, Takeshi Suzuki, Hiroko Yanagisawa, et al.. (2006). High glucose‐induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32. Journal of Neurochemistry. 98(2). 446–458. 52 indexed citations
6.
Kakehashi, Akihiro, Yoshimasa Saito, Kazuki Mori, et al.. (2005). Prevention of Diabetic Ocular Complications in Spontaneously Diabetic Torii Rats by the Aldose Reductase Inhibitor Fidarestat. Annals of the New York Academy of Sciences. 1043(1). 936–936. 1 indexed citations
7.
Obrosova, Irina G., Pál Pacher, Csaba Szabó, et al.. (2005). Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications. Diabetes. 54(1). 234–242. 141 indexed citations
8.
Li, Weiguo, Yoji Hamada, Eitaro Nakashima, et al.. (2003). Suppression of 3-deoxyglucosone and heparin-binding epidermal growth factor-like growth factor mRNA expression by an aldose reductase inhibitor in rat vascular smooth muscle cells. Biochemical and Biophysical Research Communications. 314(2). 370–376. 8 indexed citations
9.
Amano, Shinjiro, Sho‐ichi Yamagishi, Noriaki Kato, et al.. (2002). Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochemical and Biophysical Research Communications. 299(2). 183–188. 47 indexed citations
10.
Kanda, Kenro, et al.. (1998). Caracterlzatlon of the Neurochemical Effects N-(2-(l-azabicyclo(3,3,0)octan-5-yl)ethyl)2-nitroaniline fumarate (SK-946) as a Cognition Activator.. Biological and Pharmaceutical Bulletin. 21(7). 704–709. 6 indexed citations
11.
Kanda, Kenro, et al.. (1998). Effects of N-(2-(1-Azabicyclo(3,3,0)octan-5-yl)ethyl)2-nitroaniline Fumarate (SK-946), a Novel Cognition Activator, on Learning and Memory in Rodent Models.. Biological and Pharmaceutical Bulletin. 21(7). 698–703. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teresa Chen Breakdown of academic impact, for papers by Mahmood Mozaffari Breakdown of academic impact, for papers by Kiyoshi Omura Breakdown of academic impact, for papers by Pere Julià Breakdown of academic impact, for papers by С. И. Ковтун Breakdown of academic impact, for papers by G Auricchio Breakdown of academic impact, for papers by Y. Suresh Breakdown of academic impact, for papers by M Hayakawa Breakdown of academic impact, for papers by Aniruddh Kapoor
Rankless by CCL
2026